Stock Exchanges approve SeQuent–Viyash Merger

Hyderabad: Sequent Scientific (SeQuent), a player in the global animal health industry, has announced that it has secured approvals from both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) for its proposed merger with Hyderabad-based Viyash Life Sciences (Viyash). The company has now filed for clearance with the National Company Law Tribunal (NCLT) and awaiting approval for the proposed merger.

The merger will bring together two business verticals—Global Animal Health and API business unlocking access to over 150 countries. The combined entity will benefit from a five-fold increase in R&D talent and a nine-fold expansion in USFDA-approved manufacturing capacity, creating a robust and scalable operating backbone.

Rajaram Narayanan, Managing Director of SeQuent Scientific, said: “We are pleased that our proposed merger with Viyash Life Sciences is progressing as planned. This merger will accelerate a compelling new journey for SeQuent as a leading player in animal health, and Viyash with its world-class R&D capabilities and USFDA-approved facilities. FY 2024–25 marks a pivotal year for us, with strong business results as we accelerate our growth and lay the foundation for the next phase of growth. With Viyash joining us, we are poised to become a significantly stronger business—2X in scale, capability, and opportunity.”